Mass cytometry papers in blood cancers from 2020

Patients with multiple myeloma are more susceptible to infections. Authors conducted mass cytometry research to identify predictive markers for infection. No detection of phenotypic or numerical differences in immune cell populations between patients that did and did not develop infections. Transcriptional profiling of stimulated PBMCs revealed distinct Th2 immune pathway signatures in patients that developed infection.

Analysis of CD8+CD57+ terminal effector T cells in the bone marrow and peripheral blood of age-matched controls and patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), and newly diagnosed (ND) MM

Comparison between Hodgkin lymphoma biopsies and control reactive lymph node/tonsil samples. In Hodgkin lymphoma: expression of T helper 1 (Th1)-polarized Teffs and regulatory T cells (Tregs).

Study of NK cell therapy in leukemia patients. NKG2A is a dominant, transcriptionally-induced checkpoint important for ML, but not conventional NK cell responses to cancer. The frequency of CD8a+ donor NK cells is negatively associated with AML patient outcomes after ML NK therapy

Study of the peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial. CD4+, but not CD8+, TCR diversity significantly increased during therapy, most strikingly in patients who had achieved complete responses. Responders show a newly identified CD3−CD68+CD4+GrB+ subset and activated NK cell subset.

Phase I trial involving sorafenib, plerixafor and G-CSF

Combination of mass cytometry, single cell genomics, and functional studies to characterize the BM immune environment in children with B cell acute lymphoblastic leukemia and acute myelogenous leukemia at presentation

Mass cytometry analysis of sequential samples from two patients demonstrated resistance emerging early on from sub‐clones with persistent Akt and/or ERK signaling

Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative drug candidate on human
patient-derived AML cells showed an increase of CD11b and decrease of CD33+, CD7+, CD206+,
and CD38bright cells followed apoptosis after treatment ex vivo.

Characterization the bone marrow immune environment in children with B-cell acute lymphoblastic leukemia, and acute myelogenous leukemia at presentation. T cells in leukemia marrow demonstrate evidence of chronic immune activation and exhaustion/dysfunction, , with attrition of naïve T cells and TCF1+ stem-like memory T cells and accumulation of terminally-differentiated effector T cells.

Mass cytometry shows that TIGIT is highly expressed on intratumoral T cells and its expression alters T cell phenotype in Follicular Lymphoma. Increased numbers of TIGIT+ T cells are associated with inferior patient outcomes and poor survival.

Systemic reduction in natural killer (NK) cell numbers in SRα-tTA/Tet-O-MYCON mice bearing MYC-driven T-lymphomas. CyTOF provided a rationale for developing NK cell-based therapies to effectively treat MYC-driven lymphomas in the future.

Daratumumab’s effects on immune cells in whole blood samples of relapsed/refractory Multiple Myeloma patients from both treatment arms (lenalidomide/dexamethasone or daratumumab plus Rd) at baseline and after 2 months on treatment using mass cytometry. CyTOF showed NK cell reduction with Daratumumab-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep responders to Daratumumab-Rd, with a higher proportion of CD8+ versus CD4+ T cells.

Aggregate IDO1+ dendritic cell populations occur in the chronic myelomonocytic leukemia bone marrow microenvironment, and their presence correlates with disease progression.

Mass cytometry finds that deoxyguanosine and forodesine kill SAMHD1-deficient malignant cells in patients with chronic lymphocytic leukemia (CLL). Normal cells and CLL cells from patients without SAMHD1 mutation are unaffected by treatment. CyTOF could distinguish between all populations.

VEGF/VEGFRs correlates with chemotherapy resistance in AML
VEGF/VEGFRs correlates with poor clinical outcome in AML

Masss cytometry revealed an increase in activated CD4 T, CD8 T, CD8+ natural killer T‐like and NK cells in Multiple Myeloma in Bone Marrow

Association between T cell infiltration in the bone marrow microenvironment of newly diagnosed patients with AML and increased overall survival.

Healthy B cell isolates were limited to 3 major phenotypically discrete clusters, CLL samples allocated 14 independent phenotypic clusters. Mutated CLL cells were phenotypically different from unmutated CLL cells and shared only 1 phenotypic cluster.

Treatment of myeloma cells with dexamethasone or bortezomib and the authors studied the effect of the treatment with mass cytometry. Increased amounts of phosphorylated cAMP and the pro-survival protein MCL-1 were defining features of cells surviving drug treatment. CyTOF analysis of patient bone marrow cells identified myeloma cells and their key cell survival features.

Mass cytometry proves that CD163, CD68, S100A9, CCR2, CD36, Slan, and CD32 should be measured to effectively characterize lymphoma-specific tumor macrophages

Identification of novel Hodgkin lymphoma: mass cytometry highlited an association with a subset of LAG3+ T cells

Investigate the feasibility and safety of haploidentical natural killer (NK) cell infusions as consolidation immunotherapy. Multiparametric mass cytometry analysis demonstrated an altered surface receptor repertoire of expanded NK cells with increased degranulation and cytokine production activities but diminished expression of perforin.

TBL1XR1 mutation skews the humoral immune response toward producing memory B cells.

Administration of TGF-β inhibitor with stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC). Study of the blood. Treatment with galunisertib was associated with a decrease in the frequency of activated T regulatory cells in the blood. Non-progressors also had increased CD8+PD-1+TIGIT+ T cells in the blood after treatment.

Study of combination treatment f daratumumab to pomalidomide and lowdose dexamethasone. Immunophenotypic changes were analyzed in peripheral blood.

​